Search

Your search for "qsam" returned the following results.
Filter Results:
InvestorNewsBreaks

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Working to Make a Difference in Underserved Patient Populations

September 30, 2022

QSAM Biosciences (OTCQB: QSAM) is a clinical-stage biotechnology company focused on developing and bringing to market targeted therapeutic radiopharmaceuticals and advancing the fight against cancer, including the underserved pediatric population. “With the overall incidence of childhood cancer on the rise, the work of QSAM is becoming increasingly important… According to Children’s Cancer Cause, in 2022, […]

News Articles

QSAM Biosciences Inc. (QSAM) Working to Halt, Regress Bone Tumors in Children Through Therapeutic Radiopharmaceuticals

September 20, 2022

Overall incidence of childhood cancer is on the increase, averaging 0.8% increase per year since 1975, reports leading advocacy organization QSAM developing therapeutic radiopharmaceuticals as safer, more efficacious alternatives to address unmet medical needs, underserved patient populations Company creating pipeline of novel radiotherapeutics to serve multiple indications with its lead product, CycloSam With the overall […]

InvestorNewsBreaks

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Receives ‘Marketable Advantage’ Toward Manufacturing, Supply Chain of CycloSam(R)

August 25, 2022

QSAM Biosciences (OTCQB: QSAM) recently received a key patent for its exclusive radiopharmaceutical drug candidate, CycloSam(R), from the U.S. Patent & Trademark Office. “The patent protects how CycloSam is formulated and prepared, namely by using a nonradioactive kit that can be delivered and stored local to the administration site and provides for high purity in […]

InvestorNewsBreaks

InvestorNewsBreaks – QSAM Biosciences Inc. (OTCQB: QSAM) Releases Q2 2022 Financial Report, Corporate Update

August 16, 2022

QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP, or CycloSam(R), for the treatment of bone cancer and related diseases, has reported on its financial results for Q2, the period ended June 30, 2022; the company also noted that progress has been shown in its phase 1 clinical program designed to evaluate […]

News Articles

QSAM Biosciences Inc. (QSAM) Awarded Patent for Potential Breakthrough Bone Cancer Treatment

This is the third U.S. patent granted to QSAM, further strengthening its IP portfolio, which consists of 14 patents among three patent families. “CycloSam has potential to be a breakthrough therapy for both primary and secondary forms of bone cancer,” says QSAM CEO. Patent covers formulation and preparation of CycloSam in the U.S. QSAM Biosciences […]

InvestorNewsBreaks

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Targeting Significant Unmet Medical Need with CycloSam(R)

July 28, 2022

QSAM Biosciences (OTCQB: QSAM) is a company developing a new class of drugs called radiopharmaceuticals that deliver radiation therapy directly and specifically to cancer cells. The company’s lead drug candidate, CycloSam(R), is a clinical-stage bone-seeking radiopharmaceutical designed to deliver targeted radiation safely and precisely to tumors in the bone. “QSAM is leading the charge to […]

InvestorNewsBreaks

InvestorNewsBreaks – Why QSAM Biosciences Inc. (QSAM) Is ‘One to Watch’

July 22, 2022

QSAM Biosciences (OTCQB: QSAM), a clinical-stage biotechnology company, is focused on bringing to market targeted therapeutic radiopharmaceuticals. “The company is committed to advancing the fight against cancer through the discovery, development and delivery of effective treatment options for adult and pediatric patients,” a recent article reads. “CycloSam(R), QSAM Biosciences’ initial technology, is a clinical-stage bone […]

News Articles

QSAM Biosciences Inc. (QSAM) Marks Milestone with Dosing of First Patient in CycloSam Clinical Trial

July 19, 2022

Treating patients with primary or secondary bone cancer remains goal, says company CEO Radiopharmaceuticals is a new class of drugs that delivers radiation therapy directly to cancer cells QSAM is working to develop CycloSam(R) as a breakthrough therapeutic for adult and pediatric bone cancer patients QSAM Biosciences (OTCQB: QSAM), a company developing a new class of […]

InvestorNewsBreaks

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Expands IP Estate with Receipt of Third US Patent for CycloSam(R)

July 13, 2022

QSAM Biosciences (OTCQB: QSAM) is a company developing next-generation targeted therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (“CycloSam(R)”), for the treatment of cancer and related diseases. The company today announced that the United States Patent & Trademark Office has granted a key patent protecting how CycloSam(R) is formulated and prepared, namely by using a nonradioactive kit that can […]

Press Releases

QSAM Biosciences Receives Third U.S. Patent for Clinical-Stage Radiopharmaceutical Drug Candidate CycloSam®

AUSTIN, Texas, July 13, 2022 (GLOBE NEWSWIRE) — via Investorwire — QSAM Biosciences Inc. (OTCQB: QSAM) (the “Company”), a company developing next-generation targeted therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®), for the treatment of cancer and related diseases, announces today that the United States Patent & Trademark Office has granted a key patent protecting how CycloSam® is formulated and prepared, […]

News Articles

QSAM Biosciences Inc. (QSAM) Is ‘One to Watch’

July 7, 2022

QSAM Biosciences Inc. is committed to advancing the fight against cancer through the discovery, development and delivery of effective treatment options for adult and pediatric patients CycloSam(R), QSAM Biosciences’ initial technology, is a clinical-stage bone targeting radiopharmaceutical being evaluated for multiple indications CycloSam has been shown to cause significantly less buildup of long-lived radionuclidic impurities […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).